CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Dana-Farber Cancer Institute
VA Office of Research and Development
Celgene
Sumitomo Pharma America, Inc.
Pharmacyclics LLC.
Pharmacyclics LLC.